Piedmont Pharmaceuticals believes soft chew medicines will have value as part of a post patent strategy and will improve compliance with the medicating process.
Greensboro, NC (PRWEB) November 19, 2013
In June, the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category.
Beyond the Animal Health sector, this soft chew formulation is patented for use in delivering human pharmaceutical medications orally. Piedmont has demonstrated positive data supporting the use of two common OTC medications in a berry flavored soft chew.
According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “We are looking to partner with human Pharmaceutical companies to bring this novel formulation to patients. We believe soft chew medicines will have value as part of a post patent strategy and will improve compliance with the medicating process. As an example, there are consumers who struggle or dislike swallowing pills and for whom a chewable is much more acceptable.” In addition, Johnson noted that, “this formulation has been issued multiple US and international patents in the past two years.”
Piedmont Pharmaceuticals is a company that develops innovative FDA and EPA regulated medicines, medical devices and related technologies for animal and human use.